Asceneuron initiates neuroimaging trial for tau modifier ASN120290

Major milestone in development of novel treatment for progressive supranuclear palsy and other tau-related dementias

Asceneuron SA, an emerging leader in the development of innovative small molecules for the treatment of neurodegenerative diseases, announced today it has commenced a new clinical trial of its lead asset, ASN120290. The study aims to quantify target engagement of ASN120290 in the human brain using positron emission tomography (PET) to help guide dose selection for a planned clinical efficacy trial in PSP. ASN120290 has the potential to become a first-in-class treatment for progressive supranuclear palsy (PSP), a rapidly progressing rare neurodegenerative disorder, and other tau-related dementias.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH